Search research articles
Contact Us
Filters
Showing results (251-260 of 263) with videos related to
Page
of 27
Sort By:
Clinical Pharmacology and Therapeutics
|
April 1, 1992
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin
L Bertilsson, Y Q Lou, Y L Du, et al.
Annals of the Rheumatic Diseases
|
June 23, 2004
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept
N Feltelius, C M Fored, P Blomqvist, et al.
British Journal of Clinical Pharmacology
|
November 1, 1994
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test
L Bertilsson, J A Carrillo, M L Dahl, et al.
Pharmacogenetics
|
January 14, 2000
Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype
A Wennerholm, I Johansson, A Y Massele, et al.
Clinical Pharmacology and Therapeutics
|
March 3, 2007
CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir
F Josephson, A Allqvist, M Janabi, et al.
Clinical Pharmacology and Therapeutics
|
November 3, 1998
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype
K Herrlin, A Y Massele, M Jande, et al.
Clinical Pharmacology and Therapeutics
|
September 5, 1998
Artemisinin induces omeprazole metabolism in human beings
U S Svensson, M Ashton, N H Trinh, et al.
Clinical Pharmacology and Therapeutics
|
August 5, 2011
Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis
E Ngaimisi, S Mugusi, O Minzi, et al.
The Journal of Antimicrobial Chemotherapy
|
August 7, 2014
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment
E Ngaimisi, O Minzi, S Mugusi, et al.
Annals of the Rheumatic Diseases
|
April 15, 2005
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
J Askling, C M Fored, L Brandt, et al.
Page
of 27
Search research articles
Search
Showing results (251-260 of 263) with videos related to
Sort By:
Page
of 27
Clinical Pharmacology and Therapeutics
|
April 1, 1992
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin
L Bertilsson, Y Q Lou, Y L Du, et al.
Annals of the Rheumatic Diseases
|
June 23, 2004
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept
N Feltelius, C M Fored, P Blomqvist, et al.
British Journal of Clinical Pharmacology
|
November 1, 1994
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test
L Bertilsson, J A Carrillo, M L Dahl, et al.
Pharmacogenetics
|
January 14, 2000
Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype
A Wennerholm, I Johansson, A Y Massele, et al.
Clinical Pharmacology and Therapeutics
|
March 3, 2007
CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir
F Josephson, A Allqvist, M Janabi, et al.
Clinical Pharmacology and Therapeutics
|
November 3, 1998
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype
K Herrlin, A Y Massele, M Jande, et al.
Clinical Pharmacology and Therapeutics
|
September 5, 1998
Artemisinin induces omeprazole metabolism in human beings
U S Svensson, M Ashton, N H Trinh, et al.
Clinical Pharmacology and Therapeutics
|
August 5, 2011
Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis
E Ngaimisi, S Mugusi, O Minzi, et al.
The Journal of Antimicrobial Chemotherapy
|
August 7, 2014
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment
E Ngaimisi, O Minzi, S Mugusi, et al.
Annals of the Rheumatic Diseases
|
April 15, 2005
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
J Askling, C M Fored, L Brandt, et al.
Page
of 27